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Abstract Recently there has been growing interest in an alternative to conventional oxygen
therapy: the heated, humidiﬁed high ﬂow nasal cannula oxygen therapy (HFNC). A number
of physiological effects have been described with HFNC: pharyngeal dead space washout,
reduction of nasopharyngeal resistance, a positive expiratory pressure effect, an alveolar
recruitment, greater humidiﬁcation, more comfort and better tolerance by the patient, better
control of FiO2 and mucociliary clearance. There is limited experience of HFNC in adults. There
are no established guidelines or decision-making pathways to guide use of the HFNC therapy for
adults. In this article we review the existing evidence of HFNC oxygen therapy in adult patients,
its advantages, limitations and the current literature on clinical applications. Further research
is required to determine the long-term effect of this therapy and identify the adult patient
population to whom it is most beneﬁcial.
© 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights
reserved.
PALAVRAS-CHAVE
Oxigenoterapia
humidiﬁcada de alto
débito com cânulas
nasais;
Evidência clínica acerca da oxigenoterapia de baixo débito e humidiﬁcac¸ão ativa em
adultos
Resumo Recentemente, uma alternativa à oxigenoterapia convencional tem recebido atenc¸ão
crescente: trata-se da oxigenoterapia humidiﬁcada de alto débito com cânulas nasais (HFNC).Ventilac¸ão
não-invasiva;
Trocas gasosas;
Um número de efeitos ﬁsiológicos têm sido descritos: «lavagem» do espac¸o morto farín-
geo, reduc¸ão da resistência da nasofarige, efeito tipo «CPAP», recrutamento alveolar, maior
humidiﬁcac¸ão, maior conforto e melhor tolerância do doente, melhor controle do FiO2 e doInsuﬁciência
respiratória
«clearance» mucociliar. A experiência com HFNC em adultos ainda é limitada e de momento
não há «guidelines» para o seu uso. Neste artigo revemos a evidência existente do uso da HFNC
em adultos, as suas vantagens, limitac¸ões e a literatura mais recente sobre as suas aplicac¸ões
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clínicas. Mais investigac¸ão será necessária para determinar os efeitos a longo prazo desta
terapêutica e identiﬁcar quais as populac¸ões em que é mais benéﬁca.
© 2013 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os
direitos reservados.
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or years supplemental oxygen administration provided by
ifferent devices (such as nasal prongs, nose masks and face
asks), has been the ﬁrst line treatment for hypoxemic
espiratory failure. However the oxygen provided by these
onventional systems has several limitations. These limita-
ions do not usually have clinical consequences because the
elivered oxygen ﬂow is sufﬁcient to correct the hypoxemia.
owever, in some patients there can be serious problems.
or example, poor tolerance because of insufﬁcient humid-
ﬁcation and heating of the oxygen ﬂow or the fact that
he oxygen ﬂow supplied by these devices generally is no
ore than 15 L/min (the maximum ﬂow delivered by face-
asks). Another drawback of conventional oxygen devices
s the difference between the oxygen ﬂow delivered and
hat the exact amount of the patient’s inspiratory ﬂow is
ot precise; it can vary between 30 and 120 L/min dur-
ng respiratory failure.1--3 This means that the proportion
f humidiﬁed and oxygenated inspired gas can be very small
below 10%) depending on the extent of oxygen dilution with
oom air.2 One direct consequence is that the fraction of
nspired oxygen (FiO2) is not constant during conventional
xygen therapy and it is also unknown.
Recently growing attention has been paid to an alterna-
ive to conventional oxygen therapy. We refer to the heated,
umidiﬁed high ﬂow nasal cannula oxygen therapy (HFNC).
his system basically works with an air oxygen blender allow-
ng from 21% to 100% FiO2 and generates up to 60 L/min
ow rates. The gas is heated and humidiﬁed through an
ctive heated humidiﬁer and delivered via a single limb
eated inspiratory circuit (to avoid heat loss and condensa-
ion) to the patient through nasal cannula of large diameter
Figs. 1 and 2), the ‘‘high ﬂow nasal cannulas’’.3 This ther-
peutic alternative is mainly characterized by the fact that
Figure 1 Vapotherm and Flowrest devices.
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he patient is given a heated, humidiﬁed high ﬂow above its
aximum inspiratory ﬂow and we can have increased conﬁ-
ence about the real FiO2 being delivered to the patient.
FNC has been widely studied in pediatric patients where
t is increasingly used, however, the evidence in adults is
imited.4 There are no established guidelines or decision-
aking pathways to guide use of the HFNC therapy for
dults. In this article we review the existing evidence of
FNC oxygen therapy in adult patients, its advantages, lim-
tations and the current literature on clinical applications.
ow does HFNC work?
FNC has a number of physiological effects that could
e used to illustrate its beneﬁts. Several studies have
hown that HFNC generates a low level of positive air-
ay pressure,2,5,6 improves oxygenation, increases the
nd-inspiratory lung volume, reduces airway resistance,
ncreases functional residual capacity2,7 and ﬂushes
asopharyngeal dead space,2,8 thus helping to manage
reathing reduction in acute respiratory failure from all
auses. It also better tolerated and more comfortable for
he patient. Finally, pulmonary defence mechanisms are
estored. The main physiological effects of HFNC are shown
n Table 1.
Table 1 Physiological effects of HFNC.
- Pharyngeal dead space washout
- Reduction of nasopharyngeal resistance
- Positive expiratory pressure (PEEP effect)
- Alveolar recruitment
- Humidiﬁcation, great comfort and better tolerance
- Better control of FiO2 and better mucociliary clearance
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Pharyngeal dead space washout
The main effect of delivering high ﬂow oxygen directly
into the nasopharynx is to wash CO2 and reduce CO2
rebreathing. This allows the dead space to decrease and
increases alveolar ventilation over minute ventilation ratio.
These properties have some clinical beneﬁts for exercise
tolerance, dyspnea reduction and better oxygenation.
A few years ago, Dewan and Bell,8 studied the clinical
impact of high ﬂow oxygen on exercise tolerance and the
sensation of dyspnea. For this study, ten COPD patients
who were already receiving transtracheal oxygen were
recruited. Each subject underwent a total of four modiﬁed
progressive treadmill tests in a single-blind randomized
fashion on two separate days. Two tests were performed
with patients receiving low-ﬂow transtracheal oxygen
(LFTTO) and high ﬂow transtracheal oxygen (HFTTO), and
the other group received low and high ﬂow oxygen by nasal
prongs (NP). The ﬂows were adjusted to provide equivalent
oxygen saturation in the respective groups. The average
distance with HFTTO was 2.5 times greater than with
LFTTO, and high-ﬂow NP was 2.38 times higher compared
with low-ﬂow NP. Interestingly, there was no signiﬁcant
difference in exercise distance and dyspnea scores with
HFTTO as compared with high-ﬂow NP and LFTTO versus
low-ﬂow NP. This study shows that the use of high-ﬂow
oxygen via both transtracheal catheter and nasal prongs
signiﬁcantly increased exercise tolerance in COPD patients
when compared to low-ﬂow oxygen.
The dead space washout also has some beneﬁcial effects
in terms of oxygenation as observed by Chatila et al.9 These
investigators have conducted a prospective, nonrandom-
ized, nonblinded study aimed at comparing the effects of
high ﬂow of humidiﬁed oxygen to conventional low-ﬂow
oxygen delivery at rest and during exercise in ten patients
with COPD. After a period of rest and baseline recordings,
patients were asked to exercise on a cycle ergometer for up
to 12min. Exercising was started on low ﬂow oxygen ﬁrst;
after another period of rest, the patients repeated exercis-
ing using the high-ﬂow oxygen system, set at 20 L/min and
matched to deliver the same FiO2 as that of low ﬂow oxygen
delivery. Patients were able to exercise longer on high ﬂows
(10.0± 2.4min versus 8.2± 4.3min) with less dyspnea, bet-
ter breathing pattern, and lower arterial pressure compared
to low ﬂow delivery. In addition, oxygenation was higher
while receiving high ﬂow oxygen at rest and exercise despite
the matching of FiO2. The main conclusion of this study was
that high ﬂows of oxygen improved exercise performance in
patients with COPD and severe oxygen dependency, in part
by enhancing oxygenation.
Reduction of nasopharyngeal resistance
Another described effect is the resistance of the nasopha-
ryngeal air ﬂow. The design of the nasopharynx facilitates
humidiﬁcation and warming of inspired gas by contact with
the large surface area. By deﬁnition, this large wet sur-
face area and nasopharyngeal gas volume can account
for an appreciable resistance to gas ﬂow. In addition,
after analyzing nasal and oral ﬂow-volume loops, Shepard
and Burger showed10 that the nasopharynx has a disten-
sibility that contributes to a variable resistance. When
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nspiratory gas is drawn across this large surface area,
etraction of the nasopharyngeal boundaries results in a
igniﬁcant increase in inspiratory resistance compared to
xpiratory resistance. CPAP has been shown to reduce this
upraglottic resistance up to 60% by mechanically splinting
he airways. However, HFNC most probably minimizes the
nspiratory resistance associated with the nasopharynx by
roviding nasopharyngeal gas ﬂows that match or exceed
patient’s peak inspiratory ﬂow. This change in resistance
ranslates into a decrease in resistive work of breathing.3
ositive expiratory pressure (PEEP effect)
hysiologically a positive airway pressure effect, generated
y high ﬂow oxygen, provides a certain level of pulmonary
istending pressure and alveolar recruitment. This effect
as been documented in healthy persons by Groves and
obin.5 In their study the volunteers were ﬁtted with a high
ow nasal interface and pharyngeal pressures were recorded
ith ﬂows from 0 to 60 L/min. A ﬂow dependent genera-
ion of positive expiratory pressure was measured reaching
median pressure of 7.4 cm H2O at 60 L/min with the mouth
losed. Moreover, they found that expiratory pressures with
he mouth closed was higher than with the mouth open and
his was statistically signiﬁcant (<0.001).5 In conclusion, this
tudy shows us that there is a degree of CPAP generated with
he HFNC therapy, which is ﬂow dependent and also depen-
ent on whether the person is breathing with mouth open
r closed.
These results have been conﬁrmed by Parke et al.11
hese authors have studied the relationship between ﬂow
nd pressure with the HFNC oxygen therapy system. Fif-
een patients were invited to participate. These patients
ere scheduled for elective cardiac surgery. Measurements
ere performed with nasal high ﬂow oxygen at ﬂows of 30,
0 and 50 L/min with the patient’s mouth both open and
losed, the pressures were recorded over 1min of breath-
ng and average ﬂows were calculated via simple averaging.
here was a positive linear relationship between ﬂow and
ressure and a mean positive airway pressure of 2.7 cm H2O
t 35 L/min was measured with the mouth closed. A large
nterpatient variability was also noted by these authors.
his variability is probably due to differences in leak around
he outer part of the nasal cannula and the wide variabil-
ty in nare size. A smaller leak may create an increased
esistance to expiration resulting in higher nasopharyngeal
ressure, i.e., an increase the PEEP effect.6 Although this
spect deserves particular attention in neonates, it could
lso be potentially useful in adult patients. It might be inter-
sting in adults to minimize leaks around the cannula using
annulas sizes greater than 50% of the nare size.
In conclusion, nasal high ﬂow oxygen is not proposed as an
lternative to continuous positive airway pressures or nonin-
asive ventilation, where controlled pressures are indicated,
owever, the nasal high ﬂow oxygen might provide a bridge
o these therapies in selected patients.11lveolar recruitment effect
he high oxygen ﬂows delivered by nasal cannula may cor-
ect hypoxemia by several mechanisms and thus contribute
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o the alleviation of respiratory distress symptoms. The
ositive airway pressure effect provides a certain level of
ulmonary distending pressure and alveolar recruitment,
ut it is unclear how their use affects lung volume.12 A
ecent study by Corley et al.13 assessed twenty patients
rescribed HFNC post-cardiac surgery. Electrical lung
mpedance tomography was used to assess changes in
ung volume by measuring changes in lung impedance.
he primary objectives were to investigate the effects
f HFNC on airway pressure, end-expiratory lung volume
nd to identify any correlation between the two. Authors
easured a signiﬁcant correlation between end-expiratory
ung impedance and airway pressure compared with low-
ow; the high ﬂow nasal cannula signiﬁcantly increased
nd-expiratory lung impedance and airway pressure. Tidal
mpedance was also increased with HFNC. The authors
lso found that these results were most beneﬁcial in
atients with higher body mass indexes. In conclusion this
tudy is important because it shows that at least a part
f the improvement in oxygenation observed in patients
ith acute respiratory failure (ARF) is due to alveolar
ecruitment.
umidiﬁcation and tolerance
iven some of the reported issues associated with a con-
entional oxygen mask and breathing dry gas and cold
ir (mask discomfort, nasal dryness, oral dryness, eye
rritation, nasal and eye trauma, gastric distension and
spiration) nasal high ﬂow oxygen may have an important
ole11 and the need to heat and humidify supplemen-
al oxygen has been long debated.2 In comparison to
igh ﬂow face mask oxygen, some studies have found
etter comfort, tolerance and oxygenation and lower res-
iratory rate with HFNC.1,11,14 Chanques et al.,15 in a
tudy including 30 patients treated by high-ﬂow oxygen
herapy showed that bubble humidiﬁers delivered poor
evels of humidity and were associated with signiﬁcant
iscomfort; however the use of a heated-humidiﬁer in
atients with high-ﬂow oxygen therapy was associated with
decrease of dryness symptoms mediated by increased
umidity levels. Because high ﬂows of cold and dry oxygen
sed during HFNC therapy increase the airway resistance,
he addition of heat and humidity are compulsory with
FNC.3,16
The heated humidiﬁer system may also indirectly affect
xygenation. Active humidiﬁcation improves mucociliary
unction, facilitates secretion clearance and decrease
telectasis formation which improves the ventilation-
erfusion ratio and oxygenation.1 In a recent study by
ztrymf et al.12 about the impact of high-ﬂow nasal cannula
xygen on intensive care unit patients with acute respira-
ory failure, there were no reported interruptions of HFNC
herapy because of discomfort. In another study in which the
FNC was used for an average of 2.8± 1.8 days (maximum
days), intolerance never caused HFNC to be discontinued
nd no unexpected side effects were reported.2 Therefore,
e believe that HFNC could be considered very comfortable,
specially because all the patients chose to continue with
FNC.1
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etter control of FiO2 and better mucociliary
learance
n addition, other proposed mechanisms of action may
nclude the ability to more accurately control the patient’s
iO211,14,17 and better mucociliary clearance.11,18
Primary mechanical pulmonary defence mechanisms are
neezing, coughing, gagging and the use of natural ﬁlters,
.e., nasal hairs. The second line of defence is the mucocil-
ary transport system which traps and neutralizes inhaled
ontaminants (in mucus) and transports them up and out
f the airway, keeping the lung free from infection-causing
athogens. This critical defence system is very sensitive to
umidity. Loss of humidity can be a problem in itself.
In the clinical settings there are several situations where
oisture is reduced. It is the case of delivering gas from an
rtiﬁcial ﬂow source, such as piped oxygen, or the utiliza-
ion of an endotracheal or tracheostomy tube bypassing the
pper airway where the majority of humidiﬁcation would
aturally occur. These factors deplete the airway mucosa
f heat and moisture and this can have signiﬁcant adverse
ffects on the function of the mucociliary transport sys-
em and lead to impaired airway defence and gas exchange:
. The mucus layer becoming thick and tenacious; 2. The
hickness of the aqueous layer decreasing, causing cilia to
low down or stop; and 3. Heat loss from the epithelium
ells, making cilia beat less frequently.19
Delivering essential humidity through HFNC can prevent
rying of the airway, avoiding the inﬂammatory response
aused by the drying of the mucosa. Conditioning of the gas
an also minimize airway constriction, reducing the work
f breathing, which helps to maintain effective delivery of
xygen to the lungs. By delivering optimal humidity, patients
an maintain the function of the mucociliary transport sys-
em, clearing secretions more effectively and reducing the
isk of respiratory infection. This can be particularly impor-
ant for patients with secretion problems such as those with
OPD. All these beneﬁcial effects are directly related to
umidiﬁcation hence the name of active humidiﬁcation.20
linical evidence of HFNC
he HFNC has a good proﬁle in terms of clinical and
hysiological parameters such as dead-space washout,
asopharyngeal resistance reduction, positive pharyngeal
ressure, alveolar recruitment, oxygen dilution reduc-
ion and enhanced mucociliary function.3 These beneﬁcial
ffects led the researchers to assess this therapy in the clin-
cal setting. The main areas in which evidence is available
re shown in Table 2.
cute respiratory failure
here is limited published experience with HFNC in adults
ith ARF. Roca et al.1 were the ﬁrst to present promising
ata on respiratory and oxygenation parameters in twenty
atients in the intensive care unit (ICU). They showed
igniﬁcant improvement in both clinical and physiological
arameters after 30min of HFNC in comparison with stan-
ard facemask oxygen therapy. It is worth noting that the
edian duration of conventional treatment before starting
Clinical evidence on high ﬂow oxygen therapy and active humidi
Table 2 Main clinical evidences available of HFNC.
- Acute hypoxemic respiratory failure
- Post-extubation period
- Preintubation
- Emergency department
- Bronchoscopy and others invasive procedures
- Palliative care
- Acute heart failure
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- Others uses (SARI)
HFNC was more than 4 days, which precludes any conclusion
on the effect of HFNC in the immediate management of ARF.
In addition, HFNC was only used for 30min, so no data can
be obtained about the long-term effects of this device.
Recently, a ﬁrst experience with high-ﬂow nasal cannula
therapy has been reported by Sztrymf et al.12 in twenty
patients with persistent acute hypoxemic respiratory fail-
ure despite oxygen with conventional facemask and without
indication for immediate intubation. The etiology of ARF
was mainly pneumonia (n = 11), sepsis (n = 3) and miscel-
laneous (n = 6). These patients had a moderate to severe
respiratory failure with a median respiratory rate of 28 bpm
and a median pulse oxymetry of 93.5% under a median of
15 L/min oxygen with a facemask. The use of HFNC enabled
a signiﬁcant reduction of respiratory rate to a median of
24.5 breath per minute (p = 0.006) and a concomitant signif-
icant increase in oxygen saturation to 98.5% (p = 0.0003). The
HFNC was well tolerated with a median duration of 25.5 h
and a maximum of 156 h. In this small series, six patients
ultimately required intubation, providing a 70% success rate
for the technique. The same authors have conﬁrmed these
results in a larger cohort of patients and have identiﬁed
early predictors for HFNC failure.2 In fact, a persistence of
tachypnea, thoraco-abdominal asynchrony and lower pulse
oxymetry were signiﬁcantly more frequent in patients ulti-
mately requiring intubation. In conclusion these studies have
shown for the ﬁrst time the beneﬁcial effects of HFNC in
patients with ARF. Their main results can be summarized
as follows: (1) all respiratory parameters were improved
after 1 h of HFNC, achieving a rapid alleviation of respira-
tory distress in more severe patients; (2) use of HFNC led
to a signiﬁcant improvement in oxygenation; (3) HFNC was
well tolerated for long periods (a maximum of 7 days) with
sustained beneﬁts in patients who were not intubated; and
(4) the success rate of this technique was high (70%).
In less severe patients, HFCN was compared to facemask
oxygen therapy in a prospective randomized comparative
study conducted by Parke et al.17 Investigators analyzed the
success with the allocated therapy and subsequent need for
non invasive ventilation as principal outcomes in 60 patients
with mild to moderate hypoxemic respiratory failure. In
this study, signiﬁcantly more HFNC patients succeeded with
their allocated therapy and the rate of non invasive venti-
lation was 3 out of 29 patients with HFNC (10%) and 8 out
of 27 patients with facemask oxygen (30%). Patients with
HFNC also had signiﬁcantly fewer desaturations. According
to these authors, HFNC may be more effective than high ﬂow
facemask in treating mild to moderate hypoxemic respira-
tory failure.
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Finally, in a recent study with thirty-eight patients with
espiratory failure caused by community-acquired pneu-
onia, the use of HFNC was associated with a signiﬁcant
eduction in respiratory rate, heart rate, dyspnea score,
upraclavicular retraction, thoracoabdominal asynchrony
nd signiﬁcant improvement in a pulse oxymetry. These
mprovements were seen as early as 15--30min after the
eginning of HFNC and 6 h after for heart rate. The PaO2 was
igniﬁcantly higher after 1 h than before use of the device.
he PaO2/FiO2 ratio was signiﬁcantly improved at 1 and 24 h
hen compared with the value observed before use of HFNC,
owever there was no signiﬁcant increase in pH and PaCO2
efore, after 1 and 24 h of HFNC on arterial blood gases.2
These results obtained in the ‘‘real life’’ of the manage-
ent of ARF indicate that patients can be safely managed for
everal days with HFNC. This technique offers an effective
lternative to conventional oxygenation.12 Despite these
romising results, controlled studies are needed to assess
hether HFNC reduces intubation or not.
ostextubation period
igh-ﬂow oxygen therapy is a routine treatment for hypox-
mic respiratory failure in self extubated patients in the ICU.
his therapy is traditionally delivered via a face mask rather
han nasal cannula, because of the ﬂow limits of traditional
asal cannula and the tendency for patients in respiratory
istress to breathe through their mouths.17 Recently with
he introduction of the HFNC, due to their beneﬁcial effects
nd better tolerance demonstrated in several studies1--3,11,12
t seems worth investigating its use either to prevent or to
reat postextubation respiratory failure.3 There is limited
vailable literature about this topic. In an Italian study,21
09 patients were randomized to receive either venturi face-
ask oxygen or high-ﬂow nasal cannula oxygen. All analyzed
arameters (respiratory rate, oxygenation, device displace-
ent, comfort) favored the use of HFNC. Reintubation was
igniﬁcantly less frequent in the HFNC group (3.5%) that in
he venturi mask group (21%) although one may argue that
his latter ﬁgure seems unusually high. Nonetheless, this
tudy clearly shows the potential beneﬁt of this technique in
mproving comfort and enhancing oxygenation in the postex-
ubation period.3 In another recent study Tiruvoipati et al.,14
ompared the efﬁcacy of high-ﬂow nasal cannula oxygen and
igh-ﬂow face mask (HFFM) in ﬁfty extubated patients. All
he patients were randomized to either protocol A (HFFM fol-
owed by HFNC) or protocol B (HFNC followed by HFFM) after
stabilization period of 30min after extubation. The HFNC
roved an effective therapy delivering oxygen to extubated
atients who require high-ﬂow oxygen and the tolerance of
FNC was signiﬁcantly better than in HFFM (p = 0.01).
The use of HFNC in the decannulation process of tra-
heostomized patients in the context of difﬁcult weaning, is
nother promising area of development (Fig. 3) but there are
o publications about this yet (just personal experience).
reintubationndotracheal intubation in critically ill patients is associ-
ted with severe life-threatening complications in about 20%
ainly due to hypoxemia.22 Non-invasive ventilation can be
222
Figure 3 Use of HFNC in the decannulation process of a
tracheostomized patient for a difﬁcult weaning during its
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ctay in ICU. The patient breathes through his nasal cannula
hile maintaining the tracheostomy occluded facilitating the
ecannulation process. ICU: intensive care unit.
sed to enhance oxygenation before tracheal intubation,23
ut the mask has to be removed during the laryngoscopy
hich deprives the patient of oxygen during the proce-
ure. In these cases the nasal cannulas do not interfere
ith the laryngoscopy and HFNC could be used to deliver
xygen during the apneic period of tracheal intubation.3
recent experimental study in eight anesthetized piglets
ith collapse-prone lungs induced by lung lavage, showed
hat direct pharyngeal administration of 10 L/min oxygen
uring intubation, delayed the time to severe desaturation
uring apnea, suggesting that this technique might be useful
hen intubating critically ill patients with acute respiratory
ailure.22 The potential beneﬁt of HFNC during intubation
hould be further evaluated in a clinical study. However,
or ethical reasons, the design of the study cannot be that
f a randomized controlled trial.3 It would not be ethical
o perform a randomized controlled study comparing HFNC
nd conventional face mask oxygen because the amount of
ublished data clearly shows the superiority of HFNC.
The main question that remains without a deﬁnitive
nswer is whether or not HFNC reduces the need for intu-
ation in patients with hypoxemic acute respiratory failure.
ome clinicians have the impression that in some instances,
se of HFNC has avoided intubation; this has not yet been
hown in a controlled trial. However there are some indi-
ations in the literature that it may do so. A recent study
hich evaluated the clinical impact of HFNC in patients with
evere respiratory failure found a success rate of 68%,2 i.e.,
nly 32% of patients treated with HFNC required subsequent
echanical ventilation (invasive or non-invasive). However
e will have to wait for the results of the FLORALI study, a
andomized controlled trial that compares three methods:
onventional oxygen therapy, HFNC and HFNC with noninva-
ive ventilation.3se of HFNC in the emergency department
yspnea and hypoxemia are one of the most common com-
laints in patients who come to the emergency department
t
F
(
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ED) and oxygen therapy is one of the ﬁrst treatments pro-
ided, according to current guidelines. It can be delivered
y face mask or nasal prongs depending on the severity of
he patient’s respiratory distress. Rapid relief of the dysp-
ea and correction of hypoxemia are not always achieved by
onventional oxygen,3 to which must be added the limited
mount of oxygen supplied, the considerable imprecision
egarding exactly how much FiO2 was delivered and the
oor tolerance of oxygen by some patients because of insuf-
cient heating and humidiﬁcation.24 The potential beneﬁt
nd feasibility of HFNC in ED was recently evaluated by
prospective, observational study in a university hospital
mergency department.24 Seventeen patients with acute
espiratory failure requiring >9 L/min oxygen or ongoing clin-
cal signs of respiratory distress despite oxygen therapy were
tudied. The patients were treated with HFNC after hav-
ng received conventional oxygen therapy via a facemask.
he dyspnea rate by the Borg scale and a visual analogue
cale (VAS), respiratory rate (RR) and pulse oxymetry (SpO2)
ere collected before and 15, 30, 60min after beginning
FNC. This new device was associated with a signiﬁcant
ecrease in both dyspnea score (Borg scale from 6 to 3
p < 0.001] and VAS from 7 to 3 [p < 0.01]), RR decreased
rom 28 to 25 (p < 0.001) and SpO2 increased from 90% to 97%
p < 0.001). HFNC enabled a rapid and signiﬁcant improve-
ent of dyspnea score and other parameters. HFNC was
lso well tolerated, more comfortable and no more difﬁcult
o use than conventional oxygen therapy via a facemask.
hese results suggest that HFNC could constitute a ﬁrst line
herapy for selected patients coming to the ED with ARF.24
owever, more studies are required to show whether or not
arly application of HFNC avoids ICU admission in patients
resenting to the ED with ARF.3
ronchoscopy and others invasive procedures
uring bronchoscopy gas exchange is usually impaired
wing to sedation and mismatching of the ventilation
elationship.25 Hypoxemia is common with this technique
ecause the PaO2 usually drops approximately 20mmHg dur-
ng the procedure and the worst decrease occurs during
ronchoalveolar lavage (BAL).25--29 Age, gender and baseline
eripheral oxygen saturation (SpO2) are not reliable predic-
ive variables of hypoxemia25,30 which may persist several
ours after the procedure25,31 and increase the incidence
f cardiac arrhythmia.25,32 To avoid bronchoscopy-induced
ypoxemia, oxygen supply can be delivered by interfaces
ed with low or high gas ﬂow. An alternative method that
as been successfully used is noninvasive ventilation during
ronchoscopy procedures in high risk patients. A randomized
tudy has recently been published which includes forty-
ve patients receiving oxygen therapy during bronchoscopy
40 L/min through a venturi mask (V40), nasal cannula (N40)
nd 60 L/min through a nasal cannula (N60)]. The duration
f the procedure was similar in all groups as well as the
idazolam used (4mg in each group). Gas exchange and
irculatory variables were sampled before (FiO2 = 0.21) at
he end of bronchoscopy (FiO2 = 0.5) and thereafter (V40;
iO2 = 0.35). At the end of bronchoscopy HFNC with 60 L/min
N60) presented higher PaO2, PaO2/FiO2 and SpO2 than N40
nd V40 which were both the same. In conclusion under
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a ﬂow rate of 40 L/min both the venturi mask and HFNC
behaved in a similar way, but nasal cannula associated with
a 60 L/min ﬂow produced better results, thus supporting
its use in mild respiratory involvement.25,33 Our group has
also recently performed a randomized pilot study compar-
ing conventional oxygen administration with HFNC during
ﬁberoptic bronchoscopy in mildly hyoxemic patients which
showed a better level of comfort with the latter.34 Before
HFNC can be recommended in this setting more studies with
a wider population and more severely hypoxemic patients
are needed.
The HFNC may also be used in other invasive procedures
such as transoesophageal echocardiography or digestive
tract endoscopy when performed in hypoxemic sponta-
neously breathing patients.3
Palliative care
Respiratory signs and symptoms can be distressing for
patients, families, caregivers and physicians who care for
cancer patients35 and patients with advanced respiratory
disorders. Physicians are ethically obligated to recognize,
evaluate and consider the best treatment for dyspnea.36
Supplemental oxygen represents one such treatment modal-
ity and it is widely utilized in institutional settings as well
as at home.37 Possible beneﬁts include symptomatic and
functional improvement, as well as the perception that oxy-
gen is life-sustaining. Patients with underlying hypoxia are
more likely to beneﬁt,38 however, in certain settings there is
no signiﬁcant dyspnea reduction between hypoxic and non-
hypoxic patients.39 Two randomized double-blind cross-over
studies40,41 comparing air versus oxygen in cancer patients
with dyspnea, as well as a consecutive cohort study42 and
a metaanalysis43 in dyspneic patients, all failed to demon-
strated a symptom beneﬁt even when oxygen saturation
improved. Most recently, a randomized controlled double-
blind multinational trial of oxygen versus room air, both
via nasal cannula, in 239 outpatients with refractory dysp-
nea demonstrated no signiﬁcant differences in the palliation
of breathlessness.44 Recently, a study performed at Memo-
rial Sloan Kettering Cancer Center35 including 183 medical
records patients, analyzed the utilization of humidiﬁed high-
ﬂow nasal oxygen in oncological patients with dyspnea.
These patients had a variety of malignancies including:
hematological (29%); lung (17%); gastrointestinal (15%); sar-
coma (6%), head, neck and central nervous system (5%),
breast (4%) and other tumors (24%). The majority of patients
were administrated HFNC for hypoxia (98%; including 37
postoperative or post-procedure patients) and had under-
lying cardiopulmonary disease (93%; including contributing
thromboembolic and neurologic disease). HFNC was used in
the ICU in 72% of cases and also in the hospital ward alone or
after an ICU stay. The patients treated with the HFNC usually
improved (41%) or remained stable (44%), while 15% dete-
riorated. These patients have been treated over the past
two years and the device generally seemed well tolerated.35
Additionally, HFNC was effective in the stabilization or
improvement of respiratory difﬁculties in the majority of
treated patients, often obviating the need for ICU admission
or for invasive ventilatory treatments such as mechani-
cal ventilation. At study completion, 45% of patients were
(
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iving and 55% had died. The median time of use of HFNC was
days. There was a do-not-resuscitate (DNR) order for 101
55%) patients, either before or after device utilization.33,35
The strengths of this analysis include the fact that this
izable cohort constitutes, as far as we know, the only
linical description of the HFNC device exclusively in the
ancer population. It can be concluded that the HFNC is
afe and well tolerated, with no potential risk beyond those
ssociated with traditional oxygenation strategies (e.g.,
ammability). Among patients and health cares providers
physicians, nurses and respiratory therapists) the most
ommon anecdotal beneﬁt of HFNC compared with devices
llowing equivalent amounts of oxygen delivery is that users
re still able to eat and talk unencumbered.35 This tech-
ique provides acceptable conditions to manage respiratory
ailure in palliative patients.3
In our experience, HFNC also has signiﬁcantly improved
xygenation and cough compared with non-rebreather oxy-
en mask in severely hypoxemic end-stage patients with
nterstitial lung disorders, allowing for a better interaction
ith the families.36 While the practice might be debated,
atients with respiratory failure who have declared that
hey do not want to be intubated or resuscitated are com-
only treated with non-invasive ventilation (NIV) and could
otentially beneﬁt from HFNC.
Recently, Peters et al.45 identiﬁed ﬁfty do-not-intubate
DNI) and do-not-resuscitate (DNR) patients with hypoxemic
nd mild hypercapnic respiratory distress who were admit-
ed to the ICU and who received HFNC before proceeding to
IV. Patient diagnoses were pulmonary ﬁbrosis (15), pneu-
onia (15), Chronic Obstructive Pulmonary Disease/COPD
12), cancer (7), hematologic malignancy (7) and congestive
eart failure/CHF (3). The HFNC therapy was initiated at a
ean FiO2 of 0.67 and ﬂow rate 42.6 L/min. Mean O2 satu-
ations went from 89.1% to 94.7% (p < 0.001) and respiratory
ate 30.6--24.7 per minute (p < 0.001). It is worth noting,
owever, despite the overall illness severity, only 18% of
atients progressed to NIV, while 82% were maintained on
FNC with a median duration of 30 h. This study was obser-
ational but this topic should be studied prospectively.
cute heart failure
t is common to ﬁnd patients with acute heart failure (AHF)
ho, after being stabilized, maintain a level of dyspnea
r hypoxemia which does not improve with conventional
xygenation systems. One study by Carratalá Perales et al.46
as been recently published including ﬁve patients with
HF due to acute pulmonary edema (APE) and refractory
ypoxemia at 24 h after admission. All patients were
reated with conventional oxygen systems in a short stay
nit and non-invasive ventilation in the emergency room (3
atients with constant positive airway pressure and 2 with
bi-level pressure device) and afterwards with HFNC. The
linical, arterial blood gas parameters and the degree of
he dyspnea were improved in all patients and improvement
as observed after 24 h of treatment with HFNC system
signiﬁcant reduction in the intensity of the dyspnea,
mproved respiratory effort and tachypnea and disappear-
nce of hypoxemia). The improvement with this system may
ave two main causes: ﬁrst, this device provides a more
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onstant FiO2 and second, the use of a nasal cannula as the
nterface reduces the amount of respiratory dead space and
enerates a constant positive pressure directly proportional
o the ﬂow used and the resistance created during expi-
ation, which contributes to increased oxygenation.46,47 In
hort, the use of HFNC is a good alternative to traditional
xygenation systems for the treatment of patients with ARF
econdary to AHF due to APE that have dyspnea and refrac-
ory hypoxemia.46 It is characterized by easy administration
nd management, general perception of improved patients
olerance/comfort with minimal nasal trauma, and patients
utcomes are similar to those described with CPAP use.
hronic airway disorders
hronic obstructive pulmonary disease (COPD) and
ronchiectasis are both airway disorders characterized
y neutrophilic airway inﬂammation, mucus hypersecretion
nd retention, and impaired mucociliary transport.48--53
number of treatment strategies to improve mucociliary
learance have been employed. These include physical
ethods54 and mucoactive drugs which have been shown to
mprove mucus clearance and health related quality of life
QOL).55 Hasani et al.56 demonstrated that as few as 3 h/day
f humidiﬁcation therapy over seven days for bronchiectasis
atients signiﬁcantly increased lung mucociliary clearance
easured by radioaerosol labeling. Mall et al.57 demon-
trated in a mouse model that airway surface dehydration
eads to persistent neutrophilic airway inﬂammation with
ncreased mucus production and resultant emphysema.
aken together, these studies suggest that airway surface
ehydration may play an important role in the pulmonary
amage associated with chronic airway disorders. However,
he effects of long-term humidiﬁcation therapy (LTHT)
n patients with chronic airway disorders are currently
nknown. Recently Rea et al.48 have presented a 12-month
andomized study with 108 patients diagnosed with COPD
r bronchiectasis with daily humidiﬁcation therapy. The
im of this study was to examine the effects of LTHT on
requency of exacerbations, QOL, lung function, exercise
apacity and airway inﬂammation. A clinical diagnosis of
OPD was conﬁrmed with spirometry and deﬁned as an
EV1 of less than 70% of predicted, an FEV1/FVC ratio
70% without signiﬁcant bronchodilatador reversibility.
ronchiectasis was conﬁrmed by high-resolution computed
omography (HRCT). Patients with bronchiectasis associ-
ted with cystic ﬁbrosis or hypogammaglobulinemia were
xcluded. The results show that the patients on long-term
umidiﬁcation therapy had signiﬁcantly fewer exacerbation
ays (18.2 versus 33.5 days; p = 0.045), increased time to
rst exacerbation (median 52 versus 27 days; p = 0.0495)
nd reduced exacerbation frequency (2.97/patient/year
ersus 3.63/days/patient/year; p = 0.067) compared with
sual care. Quality of life scores and lung function improved
igniﬁcantly with humidiﬁcation therapy compared with
sual care at 3 and 12 months. In conclusion, this data
emonstrated that averaging as little as 1--2 h/day of LTHT
igniﬁcantly decreases all the parameters included in this
tudy.48
We have had the opportunity to verify the effectiveness
f the HFNC in a severe COPD patient suffering from chronic
ﬂ
a
a
aC. Gotera et al.
ough which interfered with sleep and was exacerbated
y the administration of O2. This opens new areas of
esearch in the ﬁeld of HOT, while identifying the need to
ndividualize the prescription of oxygen therapy.58
thers uses of HFNC
he experience with HFNC oxygen therapy in severe acute
espiratory infection (SARI) is limited. One study was
escribed by Rello and colleagues in adult patients with SARI
onﬁrmed 2009 inﬂuenzae/H1N1 v infection (by real-time
everse transcription polymerase chain reaction testing).59
he high-ﬂow nasal cannula was indicated in the presence
f acute respiratory failure when the patient was unable
o maintain a pulse oxymetry of more than 92% with more
han 9 L/min of oxygen using a standard face mask con-
entional delivery systems. Nonresponders were deﬁned by
heir need for subsequent mechanical ventilation. Twenty-
ve nonintubated adult patients were admitted for SARI
21 pneumonia). Twenty were unable to maintain pulse
xymetry of more than 92% with conventional oxygen admin-
stration and required HFNC oxygen therapy, which was
uccessful in 9 (45%). All 8 patients on vasopressors required
ntubation within 24 h. After 6 h of HFNC oxygen ther-
py, nonresponders presented a lower PaO2/FiO2 (median,
35 [interquartile range, 84--210] versus 73 [56--61] mmHg
< .05) and needed a higher oxygen ﬂow rate. No secondary
nfections were reported in health care workers. No noso-
omial pneumonia occurred during HFNC oxygen therapy.
hese results show that therapy with this device appears
o be an innovative and effective modality for early treat-
ent of SARI patients, but we still need more studies to
emonstrate its effectiveness in this context.59
echnical issues
FNC devices require 3 components: a patient interface, a
as delivery device to control ﬂow and FiO2, and a humidi-
er.
atient interface
everal manufacturers provide cannulas with standard
imension prongs which are designed for high-ﬂow appli-
ations. These cannulas can accommodate a high inlet ﬂow
f at least 60 L/min. The Fisher & Paykel Optiﬂow cannu-
as use a different design. The nasal prongs are held in
lace on the upper lip with an elastic over-ear head band.
here is a larger diameter ﬂex tubing proximal to the prongs
nd an around-the-neck elastic that connects to support the
eight of the connecting tube. There also are adapters for
racheostomized patients (Fig. 4).
ontrolling ﬂow and FiO2
e need to use commercially available calibrated high-
ow (0--70 L/min) oxygen ﬂow meters. To allow independent
djustment of FiO2 less than 1.0, separate high-ﬂow air
nd oxygen ﬂow meters can be connected via a ‘‘Ypiece’’
dapter. High-ﬂow air/O2 proportioner valve blenders or
Clinical evidence on high ﬂow oxygen therapy and active humidiﬁcation 225
Figure 4 HFNC nasal cannula from Fisher & Paykel.
Figure 5 Different commercially available calibrated high-
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aﬂow oxygen ﬂow meters: the iMAx FLO2hf and the Max Venturi
Flow generator.
high-ﬂow ‘‘Venturi’’ air mixing valves can be used. In any
case, an oxygen analyzer is needed to conﬁrm the FiO2 is
appropriate (Fig. 5).
Humidiﬁers
A key element for clinical use of HFNC is effective humid-
iﬁcation. The two most popular commercial HFNC devices
are the Fisher & Paykel Optiﬂow and the Vapotherm Pre-
cision Flow HFNC. They have different characteristics and
technology development (Fig. 6).
The Fisher & Paykel Optiﬂow HFNC became commercially
available in 2006. The system uses a heated humidiﬁer with
hot-plate and single-use water chamber, similar to those for
application for noninvasive or invasive mechanical ventila-
tion. Humidiﬁed gas mixtures exit the humidiﬁer through
large bore corrugated tubing that connects to the cannula
with a 15mm outer diameter adapter. A heated-wire circuit
is used to minimize condensation to prevent liquid water
from potentially obstructing the HFNC.
Vapotherm technology is different from the conventional
heated plate humidiﬁer systems. This device incorporates
a patented vapor transfer cartridge system that allows
water vapor to diffuse into the respiratory gas stream while
heating the gases to the prescribed temperature (typically
t
t
h
wigure 6 The humidiﬁer systems of Optiﬂow and Vapotherm
evices.
7 ◦C). This system is fundamentally different from the con-
entional heated plate humidiﬁer systems. The Vapotherm
evice also employs a triple lumen ‘‘jacketed’’ delivery
ube and proprietary nasal cannula optimized to maintain
emperature and to minimize condensation (rainout). These
atter two features protect the state of respiratory gases so
hat the gas reaches the patient at the same temperature
nd humidiﬁcation state that was achieved in the membrane
artridge. In 2008 Vapotherm released its Precision Flow
igh-ﬂow humidiﬁcation system where the air/O2 blender
nd oxygen analyzer are integrated within the humidiﬁer
odule.
Both Optiﬂow and Vapotherm have developed simpler
evices designed for home and hospital ward (Figs. 1 and 2).
he AIRVO 2 (Fisher & Paykel) sets a new standard for
elivering Optiﬂow to patients, providing performance and
onvenience with its integrated ﬂow generator and innova-
ive oxygen delivery system. This device is able to deliver
lose to 100% relative humidity at body temperature (37 ◦C),
ew point temperature display and precise, convenient FiO2
elivery from 21% to 80%. It is easy to set up and use with
imple controls, integrated O2 mixing, inbuilt O2 sensor and
o probes or external air supply required.
Flowrest® is Vapotherm’s high ﬂow therapy device
esigned speciﬁcally for homecare and other low acuity
nvironments. Designed with ease of use in mind, the
lowrest® is an integrated system for delivering warmed,
umidiﬁed breathing gases via a simple nasal cannula. The
evice has an integrated ﬂow generator, so no external air
ource is required.
et up of equipment
FNC is a very easy treatment to implement. Select appro-
riate size nasal cannula and circuit tubing for patient size.
fter this, connect nasal cannula to adaptor on circuit tub-
ng, and connect circuit tubing to humidiﬁer. Attach air
nd oxygen outlets and connect oxygen tubing from blender
o humidiﬁer. Attach water bag to humidiﬁer and turn on
o 37 ◦C. The water bag must run freely and be placed as
igh as possible above the humidiﬁer to achieve ﬂow of
ater into the humidiﬁer chamber. The system is then ready
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or use. These steps can vary depending on whether we use
ptiﬂow or Vapotherm devices, a conventional heated plate
umidiﬁer systems or a vapor transfer cartridge system.
Check the prongs sit well into the nares. Prongs should not
otally occlude nares. Set the high ﬂow nasal cannula sys-
em starting with low ﬂows up to prescribed ﬂows. Start off
t 6 L/min and increase up to goal ﬂow rate over a few min-
tes to allow patient to adjust to high ﬂow. Flows of 2 L per
g per minute with a maximum ﬂow of 60 L/min are recom-
ended. As a starting point use 35 L/min. Select the FiO2 to
btain the desired arterial oxygen saturation. Because ﬂows
sed are high, heated water humidiﬁcation is necessary to
void drying of respiratory secretions and to maintain nasal
ilia function. Set humidiﬁer on the desired temperature.
n the acute setting close patient monitoring is necessary,
pecially respiratory rate, heart rate, degree of chest in-
rawing, work of breathing and arterial oxygen saturation
nd even arterial blood gases where indicated. Within 2 h it
hould be possible to reduce the FiO2 and clinical stabiliza-
ion should be observed. When oxygen is reduced until a FiO2
f 40% decrease the ﬂow in 5 L/min decrements. The evolu-
ion of clinical and physiological parameters should allow us
o establish the time for step down to conventional oxygen
nd weaning of HFNC.
onclusion
FNC has been used for years in neonates with good results,
ut there is little information about treating ARF adults with
hese devices. We think that the HFNC could be used as
n intermediate therapy to improve oxygenation in adult
ritical care patients, respiratory care units and also for pal-
iative care. However, we believe that further research is
equired to determine the long-term effect of this therapy
nd identify the adult patients population to whom it is most
eneﬁcial.
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